Walvax Biotechnology (300142.SZ): Termination of clinical research on no-cell adsorption combined vaccine for acellular pertussis/B-type influenza and hemophilus influenzae.

Walvax Biotechnology (300142.SZ) announced that the "Adsorbed Cell-free Diphtheria, Tetanus, Pertussis, Haemophilus influenzae type b Conjugate Vaccine" jointly developed by the company and its subsidiary Yuxi Walvax Biotechnology Technology Co., Ltd. obtained the "Notice of Drug Clinical Trial Approval" in March 2022, with acceptance number: CXSL2101502. Subsequently, the company organized and conducted the corresponding clinical research work according to relevant requirements. The DTaP-Hib quadrivalent vaccine is intended for vaccination of infants aged 3 months and older to prevent pertussis, diphtheria, tetanus, as well as invasive diseases caused by Haemophilus influenzae type b such as meningitis, pneumonia, sepsis, cellulitis, arthritis, epiglottitis, etc. Since 2024, national policies have explicitly aimed to prioritize more resources for the development of urgently needed combination vaccines in clinical trials. The company actively responded to the policy call, considering that similar products are already on the market in China, and this vaccine, based on the adsorbed cell-free diphtheria, is unable to demonstrate a significant advantage over similar products; at the same time, to accelerate the upgrading of other products by focusing on key products and concentrating resources on developing next-generation combination vaccines based on the multi-component pertussis vaccine, the company has decided to terminate the clinical research related to the DTaP-Hib quadrivalent vaccine after rigorous evaluation. The termination of the clinical research work on the DTaP-Hib quadrivalent vaccine will not have a significant impact on the company's daily operations and other research and development projects, nor will it have a major impact on the company's business performance.